<DOC>
	<DOCNO>NCT01683123</DOCNO>
	<brief_summary>Analyze result condition once-daily dose intravenous busulfan fludarabine patient undergo HLA identical sibling Allogeneic HSCT myeloid malignancy .</brief_summary>
	<brief_title>Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT</brief_title>
	<detailed_description>In study investigator evaluate condition regimen consist Fludarabine 40 mg/m2 daily i.v 60 min . day -6 -3 ( total dose 160 mg/m2 ) , follow Busulfan 3,2 mg/kg daily i.v . 180 min . day ( total dose 12,8 mg/kg ) . No busulfan pharmacokinetic monitoring perform . Graft versus host disease prophylaxis consist combination cyclosporine methotrexate . Graft product obtain bone marrow peripheral blood HLA identical sibling donor manipulate cellular content transplantation . Blood product leukocyte deplete irradiated transfusion . Supportive care , include seizure prophylaxis , isolation measure , antiemetic , antimicrobial agent growth factor use follow accord standard procedure . The main objective record data regard engraftment , regimen related toxicity outcome different patient population accord age , disease type , disease status HSCT comorbidities .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Acute Myeloid Leukemia Myelodysplastic Syndrome Myeloproliferative Disorders Chronic Myeloid Leukemia Performance status ECOG &gt; 2 Cardiomyopathy ( LVEF &lt; 39 % ) Pulmonary dysfunction ( DLCO &lt; 39 % ) Hepatic dysfunction Grade &gt; 1 Renal dysfunction Grade &gt; 1 ( Creatinine &gt; 1.6 mg/dl ) HIV infection Other active neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Allogeneic HSCT</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabina</keyword>
</DOC>